Table 2.
Inhibitory effects of purified compounds on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB.
| Compound | Superoxide Anion Generation | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μM) a | Inh % b | IC50 (μM) | Inh % | |
| 26 | 6.1 ± 0.3 | 69.9 ± 4.4 *** | – c | 11.8 ± 2.1 ** |
| 54 | 4.5 ± 0.3 | 93.6 ± 3.3 *** | – | 23.7 ± 1.1 *** |
| 55 | 4.1 ± 0.2 | 99.0 ± 1.9 *** | 3.8 ± 0.1 | 89.4 ± 4.5 *** |
| 57 | 5.0 ± 0.4 | 88.4 ± 5.3 *** | 4.7 ± 0.4 | 89.9 ± 2.2 *** |
| 63 | 9.3 ± 0.3 | 52.5 ± 1.2 *** | 4.9 ± 0.2 | 75.2 ± 3.2 *** |
| 65 | 1.9 ± 0.2 | 89.3 ± 2.9 *** | 6.4 ± 0.7 | 61.3 ± 4.7 *** |
| 66 | – | 27.4 ± 7.5 * | 7.7 ± 0.5 | 60.4 ± 2.3 *** |
| 67 | 3.2 ± 0.1 | 100.0 ± 1.3 *** | 4.1 ± 0.7 | 99.6 ± 7.6 *** |
| 70 | 5.6 ± 0.9 | 85.2 ± 9.7 *** | – | 46.5 ± 2.2 *** |
| LY294002 d | 1.0 ± 0.2 | 3.1 ± 0.7 | ||
Results are presented as mean ± SEM (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control (DMSO). a Concentration necessary for 50 % inhibition (IC50). b Percentage of inhibition (Inh %) at 10 μM concentration. c Not determined. d A phosphatidylinositol-3-kinase inhibitor was used as a positive control.